Convalescent plasma for people with COVID-19: a living systematic review

Iannizzi, Claire; Chai, Khai Li; Piechotta, Vanessa; Valk, Sarah J; Kimber, Catherine; Monsef, Ina; Wood, Erica M.; Lamikanra, Abigail; Roberts, David; McQuilten, Zoe; So‐Osman, Cynthia; Jindal, Aikaj; Cryns, Nora; Estcourt, Lise J; Kreuzberger, Nina; Skoetz, Nicole

doi:10.1002/14651858.cd013600.pub6

Cited by 13 publications

(14 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings contribute valuable information regarding therapeutic dose for overweight patients during a pandemic, suggesting that consecutive transfusions of CCP units can be safely administered, similar to studies in patients with moderate to severe COVID-19. 26 In our study, various safety measures were implemented that were likely the drivers preventing adverse events. For example, the hematologist set up different strategies such as the slow transfusion drip rates, pre-transfusion prescription of acetaminophen and diphenhydramine to the patients, and the careful selection of donors with characteristics such as being male or female without previous pregnancies or testing negative for anti-HLA antibodies.…”

Section: Discussionmentioning

confidence: 98%

Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID‐19: An early phase 1 descriptive study

Aguilar,

López‐Vergès,

Quintana

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundAt the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, transfusion of coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) emerged as a potential therapeutic strategy to help patients severely afflicted by COVID‐19. The efficacy of CCP has been controversial as it depends on many variables pertaining to the plasma donor and the patient with COVID‐19, for example, time of convalescence or symptoms onset. This feasibility and descriptive study aimed to assess the safety of multiple doses of CCP in mechanically ventilated, intubated patients with respiratory failure due to COVID‐19.MethodsA cohort of 30 patients all experiencing severe respiratory failure and undergoing invasive mechanical ventilation in an intensive care unit, received up to five doses of 300–600 mL of CCP on alternate days (0, 2, 4, 6, and 8) until extubation, futility, or death.ResultsNineteen patients received five doses, seven received four, and four received two or three doses. At 28‐day follow‐up mark, 57% of patients recovered and were sent home, and the long‐term mortality rate was 27%. Ten severe adverse events reported in the study were unrelated to CCP transfusion. Independent of the number of transfused doses, most patients had detectable levels of total and neutralizing antibodies in plasma.ConclusionThis study suggests that transfusion of multiple doses of CCP is safe. This strategy may represent a viable option for future studies, given the potential benefit of CCP transfusions during the early stages of infection in unvaccinated populations and in settings where monoclonal antibodies or antivirals are contraindicated or unavailable.

show abstract

Section: Discussionmentioning

confidence: 98%

Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID‐19: An early phase 1 descriptive study

Aguilar,

López‐Vergès,

Quintana

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…Several thoughtfully-conceived post-hoc [ 37 ] and meta-analyses [ 48 ] indicate an overall survival benefit, particularly when CCP is administered soon after infection [ 37 ] with a higher titer of virus-specific antibody [ 37 ] from geographically-proximate donors [ 49 ]. Other meta-analyses have not confirmed benefit for differences in WHO score or mortality among hospitalized patients on noninvasive supplemental oxygen [ 47 , 50 ]. Selected data suggest greatest benefit from CCP in hospitalized patients who are immuncompromised [ 46 ], unvaccinated [ 44 ], who have not yet developed specific antibodies, or who are not receiving other targeted therapy (e.g., remdesivir and corticosteroids) [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise

Janoff

Brown

Belitskaya-Lévy

et al. 2023

Contemporary Clinical Trials Communications

View full text Add to dashboard Cite

“…Following the early positive experience in hospitalized COVID-19 patients from China and Italy [18], CCP was the object of intense research from investigators worldwide and, among anti-COVID-19 therapies, it has been the most extensively studied, being its safety and efficacy assessed by more than 30 randomized controlled trials (RCTs) and more than 100 non-RCTs so far, whose results have been fully published [19,20]. A strong inverse correlation between CCP use and mortality per admission in USA was observed during the winter 2020-2021 [21].…”

Section: Hospitalized Patientsmentioning

confidence: 99%

Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review

Franchini,

Focosi

2024

Life

View full text Add to dashboard Cite

Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed to fight this not rarely life-threatening respiratory illness. Among them, however, the only specific antibody-based therapy available against SARS-CoV-2 infection during the first year of the pandemic was represented by COVID-19 convalescent plasma (CCP). CCP, collected from recovered individuals, contains high levels of polyclonal antibodies of different subclasses able to neutralize SARS-CoV-2 infection. Tens of randomized controlled trials have been conducted during the last three years of the pandemic to evaluate the safety and the clinical efficacy of CCP in both hospitalized and ambulatory COVID-19 patients, whose main results will be summarized in this narrative review. In addition, we will present the current knowledge on the development of anti-SARS-CoV-2 hyperimmune polyclonal immunoglobulins.

show abstract

Convalescent plasma for people with COVID-19: a living systematic review

Cited by 13 publications

References 200 publications

Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID‐19: An early phase 1 descriptive study

Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID‐19: An early phase 1 descriptive study

Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise

Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review

Contact Info

Product

Resources

About